Výsledky vyhledávání

Doing good badly? Philosophical issues related to effective altruism

Autor: Plant, M

Suppose you want to do as much good as possible. What should you do? According to members of the effective altruism movement—which has produced much of the thinking on this issue and counts several moral philosophers as its key protagonists—we sh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::33b7ea457abdc207e8b50e7759b464ec
https://ora.ox.ac.uk/objects/uuid:59a79c4f-2a25-4ea7-afa6-aa04c1537acf

Zobrazit plný text záznamu

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis

Autor: Jani, Meghna, Chinoy, Hector, Warren, Richard B., Griffiths, Christopher E. M., Plant, Darren, Fu, Bo, Morgan, Ann W., Wilson, Anthony G., Isaacs, John D., Hyrich, KimmeL., Barton, Anne, Prouse, P. J., Moitra, R. K., Shawe, D. J., Nisar, M., Fairburn, K., Nixon, J., Barnes, T., Hui, M., Coady, D., Wright, D., Morley, C., Raftery, G., Bracewell, C., Bridges, M., Armstrong, D., Chuck, A. J., Hailwood, S., Kumar, N., Ashok, D., Reece, R., O'Reilly, S. C., Ding, T., Badcock, L. J., Deighton, C. M., Raj, N., Regan, M. R., Summers, G. D., Williams, R. A., Lambert, J. R., Stevens, R., Wilkinson, C., Kelly, C. A., Hamilton, J., Heycock, C. R., Saravanan, V., Cope, A., Garrood, T., Ng, N., Kirkham, B., Green, M., Gough, A., Lawson, C., Das, D., Borbas, E., Wazir, T., Emery, P., Bingham, S., Bird, H. A., Conaghan, P.G., Pease, C. T., Wakefield, R. J., Buch, M., Bruce, I., Gorodkin, R., Ho, P., Parker, B., Smith, W., Jenkins, E., Mukhtyar, C., Gaffney, K., Macgregor, A. J., Marshall, T., Merry, P., DeSilva, C., Birrell, F. N., Crook, P. R., Szebenyi, B., Bates, D., James, D., Gillott, T., Alvi, A., Grey, C., Browning, J., McHale, J. F., Gaywood, I.C., Jones, A. C., Lanyon, P., Pande, I., Doherty, M., Gupta, A., Courtney, P. A., Srikanth, A., Abhishek, A., Das, L., Pattrick, M., Snowden, H. N., Bowden, A. P., Smith, E. E., Klimiuk, P., Speden, D. J., Naz, S., Ledingham, J. M., Hull, R. G., McCrae, F., Cooper, A., Young‐Min, S. A., Wong, E., Shaban, R., Woolf, A. D., Davis, M., Hutchinson, D., Endean, A., Mewar, D., Tunn, E. J., Nelson, K., Kennedy, T. D., Dubois, C., Pauling, J., Korendowych, E., Jenkinson, T., Sengupta, R., Bhalla, A., McHugh, N., O'Neil, T., Herrick, A. L., Jones, A. K., Cooper, R. G., Dixon, W. G., Harrison, B., Buckley, C. D., Carruthers, D. C., Elamanchi, R., Gordon, P. C., Grindulis, K. A., Khattak, F., Raza, K., Situnayake, K., Akil, M., Till, S., Dunkley, L., Tattersall, R., Kilding, R., Tait, T., Maxwell, J., Kuet, K.-P., Plant, M. J., Clarke, F., Fordham, J. N., Tuck, S., Pathare, S. K., Paul, A., Marguerie, C. P., Rigby, S. P., Dunn, N., Abbas, I., Filer, C., Abernethy, V. E., Clewes, A. R., Dawson, J. K., Kitas, G., Erb, N., Klocke, R., Whallett, A. J., Douglas, K., Pace, A., Sandhu, R., John, H., Shand, L., Lane, S., Foster, H., Griffiths, B., Griffiths, I., Kay, L., Ng, W.-F., Platt, P. N., Walker, D. J., Peterson, P., Lorenzi, A., Friswell, M., Thompson, B., Lee, M., Pratt, A., Hopkinson, N. D., Dunne, C. A., Quilty, B., Marks, J., Mukherjee, S., Mulherin, D., Chalam, S. V., Price, T., Sheeran, T., Venkatachalam, S., Baskar, S., Al- Allaf, W., McKenna, F., Shah, P., Filer, A., Bowman, S. J., Jobanputra, P., Rankin, E. C., Allen, M., Chaudhuri, K., Dubey, S., Price‐Forbes, A., Ravindran, J., Samanta, A., Sheldon, P., Hassan, W., Francis, J., Kinder, A., Neame, R., Moorthy, A., Bukhari, M., Ottewell, L., Palkonyai, E., Hider, S., Hassell, A., Menon, A., Dowson, C., Kamath, S., Packham, J., Dutta, S., Price, S., Roddy, E., Paskins, Z., O'Reilly, D. T., Rajagopal, V., Bhagat, S., Chattopadhyay, C. B., Quinn, D., Isdale, A., Brown, A., Saleem, B., Foo, B., Al Saffar, Z., Koduri, G.

Publikováno v: Arthritis & Rheumatology (Hoboken, N.j.)

Objective: To investigate whether antidrug antibodies and/or drug non-trough levels predict the long-term treatment response in a large cohort of patients with rheumatoid arthritis (RA) treated with adalimumab or etanercept and to identify factors in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::811f5092e9b2ad61a45e40c7a44d2c10
http://europepmc.org/articles/PMC4843946

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání